Bluebird Bio (BLUE)

Apr 16, 2025, 8:00 AM EDT - 8 days ago

bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement

Mar 31, 2025, 11:24 AM EDT - 23 days ago

Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps

Mar 28, 2025, 5:43 PM EDT - 26 days ago

Bluebird bio receives non-binding bid for up to $110.5 million

Mar 28, 2025, 5:06 PM EDT - 26 days ago

Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update

Mar 28, 2025, 4:15 PM EDT - 26 days ago

bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid

Mar 13, 2025, 3:43 PM EDT - 5 weeks ago

BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE

Feb 21, 2025, 3:43 PM EST - 2 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.

CG

Feb 21, 2025, 1:48 PM EST - 2 months ago

Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker

Feb 21, 2025, 9:45 AM EST - 2 months ago

bluebird bio Stock Alert - Kehoe Law Firm, P.C. Investigating the Fairness and Adequacy of the Proposed Acquisition of bluebird bio by Investment Firms in Collaboration with Biotech Execs

CG

Feb 21, 2025, 8:04 AM EST - 2 months ago

Bluebird bio to be taken private by Carlyle and SK Capital amid cash crunch

CG

Feb 21, 2025, 7:30 AM EST - 2 months ago

bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

CG

Feb 18, 2025, 9:52 AM EST - 2 months ago

High-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment models

CVS VRTX

Dec 8, 2024, 12:30 PM EST - 4 months ago

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Dec 7, 2024, 12:00 PM EST - 4 months ago

Long-Term Follow-Up Data Continue to Support Beti-Cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels

Dec 4, 2024, 4:05 PM EST - 5 months ago

bluebird bio Announces 1-for-20 Reverse Stock Split

Dec 4, 2024, 8:47 AM EST - 5 months ago

bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model

Nov 27, 2024, 11:45 AM EST - 5 months ago

FDA investigates risk of blood cancers from bluebird bio's gene therapy

Nov 20, 2024, 8:10 AM EST - 5 months ago

My Dividend Stock Portfolio: New October Dividend Record - 100 Holdings With 15 Buys

AAPL ABBV AGNC AM ARCC ARI AVGO

Nov 15, 2024, 2:05 PM EST - 5 months ago

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

Nov 14, 2024, 10:06 AM EST - 5 months ago

bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 7:00 AM EST - 5 months ago

bluebird bio Reports Third Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Nov 6, 2024, 4:15 PM EST - 6 months ago

bluebird bio Adjourns Meeting of Stockholders and Announces Third Quarter Results Call

Nov 5, 2024, 9:05 AM EST - 6 months ago

bluebird bio to Present Additional Long-Term Follow-up Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

Oct 8, 2024, 3:53 PM EDT - 7 months ago

Bluebird Bio (BLUE) Stock Dips Amid Market Volatility

Oct 6, 2024, 2:00 PM EDT - 7 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BMY CRSP EDIT EXAS NTLA

Oct 4, 2024, 4:05 PM EDT - 7 months ago

bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2024, 4:11 PM EDT - 7 months ago

Bluebird Bio (BLUE) Stock Surges 5.04% Amid Market Movements

Sep 27, 2024, 4:30 PM EDT - 7 months ago

bluebird bio Announces Completion of its Q2 2024 Form 10-Q Filing

Sep 24, 2024, 7:08 AM EDT - 7 months ago

Bluebird bio to cut 25% of workforce as part of restructuring

Sep 24, 2024, 7:00 AM EDT - 7 months ago

bluebird bio Initiates Restructuring Intended to Optimize Cost Structure and Enable Quarterly Cash Flow Break-Even in the Second Half of 2025

Sep 13, 2024, 4:41 PM EDT - 7 months ago

bluebird bio Announces Completion of its Restatement and filing of its 2023 Form 10-K and Q1 2024 Form 10-Q

Aug 28, 2024, 8:10 AM EDT - 8 months ago

My Dividend Stock Portfolio: New July Dividend Record - 101 Holdings With 24 Buys

AAPL ABBV AGNC AM APLE ARCC ARI

Aug 28, 2024, 8:00 AM EDT - 8 months ago

bluebird bio Announces September Investor Events

Aug 23, 2024, 4:05 PM EDT - 8 months ago

bluebird bio Announces Receipt of Expected Notices from Nasdaq

Aug 14, 2024, 11:14 AM EDT - 9 months ago

bluebird bio, Inc. (BLUE) Q2 2024 Earnings Call Transcript

Aug 14, 2024, 7:00 AM EDT - 9 months ago

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

Aug 12, 2024, 8:00 AM EDT - 9 months ago

bluebird bio Announces Second Quarter 2024 Results Call Date

Aug 2, 2024, 4:05 PM EDT - 9 months ago

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 3, 2024, 4:05 PM EDT - 10 months ago

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

Jun 2, 2024, 10:15 PM EDT - 11 months ago

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

May 29, 2024, 8:56 AM EDT - 11 months ago

Bluebird bio appoints new CFO to oversee financial restatements

May 29, 2024, 7:00 AM EDT - 11 months ago

bluebird bio Appoints O. James Sterling as Chief Financial Officer